caa a22 4500 469115432 CHVBK 20180323133123.0 cr unu---uuuuu 170328e19920401xx s 000 0 eng 10.1007/BF00731706 doi (NATIONALLICENCE)springer-10.1007/BF00731706 Monoclonal antibody GOM-2 binds to blood group B-Ley active glycolipid antigens on human gastric cancer cells, KATO-III [Elektronische Daten] [Shinobu Sueyoshi, Hitomi Nagakura, Akira Kato, Setsuyoshi Uetsuki, Yasuo Nakayama, Masakazu Adachi] The antigen structure of a mouse monoclonal antibody, GOM-2, established by immunization with KATO-III human gastric cancer cells, was examined. GOM-2 reactive glycolipids were prepared from KATO-III cells and treated with endoglycoceramidase. Structural studies of ten GOM-2 reactive oligosaccharides by a combination of glycosidase digestions, methylation, and affinity chromatography on anUlex europeus agglutinin I (UEA-I) column revealed that nine of them had a Y-related B-active difucosylated determinant (B-Ley) and one had a B-active determinant. Affinity chromatography of the purified and modified oligosaccharides on an immobilized GOM-2 column demonstrated that GOM-2 has a novel binding specificity; it binds tightly to the biantennary structure carrying the B-Ley determinant at the termini or the branched structure carrying the B-Ley structure at two nonreducing termini. Chapman & Hall, 1992 B-Ley active glycolipids nationallicence monoclonal antibody nationallicence UEA-I : Ulex europeus agglutinin I nationallicence PNA : Arachis hypogaea agglutinin nationallicence Fuc : l-fucose nationallicence Gal : d-galactose nationallicence Glcol : glucitol nationallicence GlcNAc : N-acetyl-d-glucosamine nationallicence TBS : 10mm Tris-HCl, pH 7.8, containing 150mm NaCl nationallicence PBS : 10mm sodium phosphate buffer, pH 7.5, containing 150mm NaCl nationallicence HPLC : high performance liquid chromatography nationallicence Sueyoshi Shinobu Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut Nagakura Hitomi Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut Kato Akira Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut Uetsuki Setsuyoshi Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut Nakayama Yasuo Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut Adachi Masakazu Japan Immunoresearch Laboratories, 370, Takasaki, Gunma, Japan aut Glycoconjugate Journal Kluwer Academic Publishers 9/2(1992-04-01), 99-108 0282-0080 9:2<99 1992 9 10719 https://doi.org/10.1007/BF00731706 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00731706 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sueyoshi Shinobu Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut NATIONALLICENCE 700 1- Nagakura Hitomi Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut NATIONALLICENCE 700 1- Kato Akira Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut NATIONALLICENCE 700 1- Uetsuki Setsuyoshi Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut NATIONALLICENCE 700 1- Nakayama Yasuo Formulation Research Institute, Otsuka Pharmaceutical Company, 771-01, Tokushima, Japan aut NATIONALLICENCE 700 1- Adachi Masakazu Japan Immunoresearch Laboratories, 370, Takasaki, Gunma, Japan aut NATIONALLICENCE 773 0- Glycoconjugate Journal Kluwer Academic Publishers 9/2(1992-04-01), 99-108 0282-0080 9:2<99 1992 9 10719 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer